ALAlain Labelle

Alain Labelle

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alain Labelle has a total of 36 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Intrafamilial Homicide: A Descriptive Study of Fratricide in Quebec

    by D. Bourget, P. Gagné, A. Labelle

    Introduction: Fratricide comprises approximately 2% of all intra-familial homicides. Analyses of national data on fratricide show that adult males are considerably more likely to be offenders and victims or fratricide. A previous study suggested there were two main categories of fratricide: related to alcohol intoxication or associated with mental disorder.Objectives: Present and discuss the results of an original study comprising 28 cases of fratricide.Aims: To provide up-to-date scientific knowledge on fratricide.Method: This is a retrospective study of 28 cases of fratricides, extracted from a sample of over 1000 consecutive cases of coroners’ files of victims of domestic homicide occurring between 1990–2015.Results: Two victims out of three were males, most of adult age. There were only 2 female offenders in the whole sample. A majority of victims were Caucasians while 21% were aboriginals. Most victims were stabbed to death. The murders usually occurred at the residence of the victim. In total, 39% of offenders suffered from a major mental illness; 21% were acutely intoxicated at the time. In victims, 29% were under the influence of alcohol and 18% of offenders were free from mental problems.Conclusion: Our data indicates that fratricides are most often impulsive and lack preparation. The most common method was the opportunistic use of a knife, suggestive of impulsive killing, and this is consistent with the rest of the information including the high rate of alcohol use and intoxication at the time. The study confirmed two main categories of fratricide: impulsive killing in the context of alcohol and dispute and killing associated with psychosis.Disclosure of interest: The authors have not supplied their declaration of competing interest.


  • Open Access

    Evidence review and clinical guidance for the use of ziprasidone in Canada

    by David M Gardner, Andrea L Murphy, Stan Kutcher, Serge Beaulieu, Carlo Carandang, Alain Labelle, Pierre Lalonde, Ashok Malla, Heather Milliken, Claire O’donovan, et al.

    While indicated for schizophrenia and acute mania, ziprasidone’s evidence base and use in clinical practice extends beyond these regulatory approvals. We, an invited panel of experts led by a working group of 3, critically examined the evidence and our collective experience regarding the effectiveness, tolerability and safety of ziprasidone across its clinical uses. There was no opportunity for manufacturer input into the content of the review. As anticipated, ziprasidone was found to be effective for its indicated uses, although its utility in mania and mixed states lacked comparative data. Beyond these uses, the available data were either unimpressive or were lacking. An attractive characteristic is its neutral effect on weight thereby providing patients with a non-obesogenic long-term treatment option. Key challenges in practice include the need for dosing on a full stomach and managing its early onset adverse effect of restlessness. Addressing these issues are critical to its long-term success


  • Open Access

    Association study of the trinucleotide repeat polymorphism within SMARCA2 and schizophrenia

    by Sarojini Sengupta, Lan Xiong, Ferid Fathalli, Chawki Benkelfat, Karim Tabbane, Zoltan Danics, Alain Labelle, Samarthji Lal, Marie-Odile Krebs, Guy Rouleau, et al.

    Brahma (BRM) is a key component of the multisubunit SWI/SNF complex, a complex which uses the energy of ATP hydrolysis to remodel chromatin. BRM contains an N-terminal polyglutamine domain, encoded by a polymorphic trinucleotide (CAA/CAG) repeat, the only known polymorphism in the coding region of the gene (SMARCA2). We have examined the association of this polymorphism with schizophrenia in a family-based and case/control study. SMARCA2 was chosen as a candidate gene because of its specific role in developmental pathways, its high expression level in the brain and some evidence of its association with schizophrenia spectrum disorder from genome-wide linkage analysis. Family-based analysis with 281 complete and incomplete triads showed that there is no significant preferential transmission of any of the alleles to the affected offspring. Also, in the case/control analysis, similar allele and genotype distributions were observed between affected cases (n = 289) and unaffected controls (n = 273) in each of three Caucasian populations studied: French Canadian, Tunisian and other Caucasians of European origin. Results from our family-based and case-control association study suggest that there is no association between the trinucleotide repeat polymorphism within SMARCA2 and schizophrenia.


  • Switching Outpatients With Schizophrenia and Related Disorders on Long-Acting Injectable Antipsychotics to Olanzapine: An Open-Label Naturalistic Pilot Study

    by Alain Labelle, Dominique Bourget, Luc Jean Boulay, Jack Ellis, Pierre Tessier

    Little is known about the feasibility of switching patients with schizophrenia from long-acting injectable antipsychotics to oral olanzapine. We completed an open-label 14-week study to assess such a transition. This study included 25 stable outpatients (DSM-IV diagnosis of schizophrenia, schizophreniform disorder, or schizoaffective disorder) who were receiving long-acting injectable antipsychotics. Following a screening visit, patients began treatment with olanzapine 10 mg/day, which was initiated the day of their scheduled injection. Clinical assessments included the Clinical Global Impression—Improvement Scale (CGI-I) and the Positive and Negative Syndrome Scale (PANSS). Patient self-reports of adverse events were monitored and the Extrapyramidal Symptoms Rating Scale completed at each visit. In those completing the trial (N = 18), results revealed that a switch from injectable antipsychotics to olanzapine was associated with significant improvements on the CGI-I, negative symptoms, PANSS total scores, and parkinsonism. In considering the whole sample (last observation carried forward, N = 25), significant improvements on the CGI-I, parkinsonism, and dyskinesia were observed. Finally, those who failed to complete the trial (N = 7) did not change significantly from visit 1 to endpoint on any of the efficacy or safety measures. These results should be considered preliminary and require replication using appropriate control groups.


  • Open Access

    Retention Rates in Placebo- and Nonplacebo-Controlled Clinical Trials of Schizophrenia

    by Alain Labelle, Luc Jean Boulay, Yvon Denis Lapierre

    Objective: To determine if the inclusion of a placebo control in clinical trials of schizophrenia affects retention rates in the first 35 days of inclusion relative to trials that did not have a placebo control. Method: This was a retrospective study of 8 double-blind clinical trials, 5 of which had a placebo control while 3 did not. Using survival analysis, retention rates between the placebo-controlled trials (PCTs) and the nonplacebo-controlled trials (NPCTs) were compared. Screening and percentage improvement on Brief Psychiatric Rating Scale and Positive and Negative Syndrome Scale scores were compared. Results: Significantly more patients were retained in the 35-day period for NPCTs. Also, the PCT group had significantly more psychopathology at screening than did the NPCT group. Conclusions: Differences in retention rates between PCTs and NPCTs cannot be uniquely attributed to placebo itself.


    • 1 March 1999
      • Vol. 44  (2) , 190

    An attempted suicide using transdermal nicotine patches.

    by A Labelle, L J Boulay


    • 1 April 1991
      • Vol. 11  (2) , 149-50

    Keratodermia: side effects of lithium.

    by A Labelle, Y D Lapierre